Item 2.02. Results of Operations and Financial Condition. OnNovember 10, 2021 ,Axcella Health Inc. , doing business as "Axcella Therapeutics," announced its financial results for the third quarter endedSeptember 30, 2021 . The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Chief Financial Officer OnNovember 4, 2021 ,Laurent Chardonnet , the Chief Financial Officer of the Company, notified the Company of his resignation effective as ofNovember 28, 2021 .Mr. Chardonnet will be departing the Company for personal reasons and to pursue other interests. He will continue to serve as a consultant to the Company to ensure a smooth transition. The Company thanksMr. Chardonnet for his contributions and has initiated a search for a new Chief Financial Officer. Item 9.01. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description Press Release issued byAxcella Health Inc. , doing business as "Axcella 99.1 Therapeutics," datedNovember 10, 2021 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source